From: Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
Cell Source | Cargo | Size | Functionalization Strategy | Application | References |
---|---|---|---|---|---|
T cell | Multilamellar liposomes |  ~ 300 nm | Maleimide-cell surface thiol | B16F10 melanoma lung and bone marrow tumors | [79] |
Lipid-coated PLGA |  ~ 230 nm | Maleimide-cell surface thiol | B16F10 melanoma lung and bone marrow tumors | [79] | |
Liposomes |  ~ 200 nm | Maleimide-cell surface thiol | Prostate tumor | [80] | |
Lipid nanocapsules |  ~ 340 nm | Maleimide-cell surface thiol | Lymphoma cells | [83] | |
Liposomes |  ~ 83 nm | CD45 antibody conjugation | B16F10 melanoma | [81] | |
Cytokine nanogels |  ~ 100 nm | Covalent conjugation via crosslinker/ electrostatic interaction | B16F10 melanoma | [82] | |
Lipid nanocapsules |  ~ 240 nm* | Maleimide-cell surface thiol | Functional modification of CTLs | [84] | |
CAR T-cell | Cytokine nanogels |  ~ 80–130 nm | CD45 antibody conjugation/ electrostatic interaction | B16F10 melanoma | [78] |
Multilamellar liposomes |  ~ 160 nm* | Maleimid-cell surface thiol | SKOV 3 ovarian cancer and leukemia | [85] | |
NK cell | Liposomes |  ~ 138 nm | NK1.1 antibody conjugation | SW620 colon cancer cells | [86] |
Graphene oxide-PEG nanoclusters |  ~ 50–300 nm | CD16 antibody conjugation | Activation of NK cells | [87] | |
CAR NK- cell | Liposomes |  ~ 220 nm* | Maleimide-cell surface thiol | SKOV 3 Ovarian cancer | [88] |
Leukocyte | Liposomes |  ~ 118 nm | Binding between E-selectin receptor and apoptosis inducing ligand TRAIL | Circulating colon cancer cells (COLO 205) | [89] |
B cell | Multilamellar Liposomes |  ~ 300 nm | Maleimide-cell surface thiol | B16F10 melanoma lung and bone marrow tumors | [79] |
HSC | Multilamellar Liposomes |  ~ 300 nm | Maleimide-cell surface thiol | B16F10 melanoma lung and bone marrow tumors | [79] |